Upon joining the trial, you will be randomly assigned to one of two treatment groups. This process is called randomization and ensures fairness in the study.

You will receive either ninerafaxstat, which is the medication being tested, or a placebo, which is an inactive tablet that looks identical to the actual medication.

Neither you nor your doctor will know which treatment you are receiving. This is called a double-blinded design and helps ensure accurate results.

You will take tablets by mouth. The tablets are modified-release, which means they release the medication slowly over time.

If you are assigned to the active treatment group, you will receive ninerafaxstat trihydrochloride monohydrate.

If you are assigned to the placebo group, you will receive tablets that look exactly the same but contain no active medication.

You will need to follow the prescribed schedule for taking your tablets throughout the study period.

You will undergo echocardiography tests during the trial. This is an ultrasound examination of your heart that uses sound waves to create images.

These tests will be performed at the beginning of the trial and at scheduled intervals to monitor your heart function.

The echocardiography is painless and non-invasive.

You will complete cardiopulmonary exercise testing, abbreviated as CPET. This test measures how well your heart and lungs work during physical activity.

The test will be performed at the beginning of the trial to establish your baseline measurements.

You will repeat the same exercise test at Week 12 to measure any changes in your exercise capacity and breathing efficiency.

You will be asked to complete the Kansas City Cardiomyopathy Questionnaire, abbreviated as KCCQ. This questionnaire asks about your symptoms and how they affect your daily life.

You will complete this questionnaire at the start of the trial to record your baseline health status.

You will complete the same questionnaire again at Week 12 to assess any changes in your condition.

The questionnaire covers several areas including your overall symptoms, physical limitations, and quality of life.

Throughout the 12-week treatment period, you will attend scheduled visits for monitoring.

During these visits, your health status will be assessed and any side effects will be recorded.

You will be monitored for safety throughout the entire duration of your participation in the trial.

At Week 12, you will complete your final assessments, which include the exercise test, heart imaging, and health questionnaires.

These final measurements will be compared to your initial baseline measurements to determine if the treatment had any effect.

Your participation in the active treatment phase will conclude after these assessments are completed.